{
    "title": "114_hr639",
    "content": "The \"Improving Regulatory Transparency for New Medical Therapies Act\" requires that drug approval under the Controlled Substances Act will not take effect until the interim final rule controlling the drug is issued. The \"Improving Regulatory Transparency for New Medical Therapies Act\" stipulates that drug approval under the Controlled Substances Act will only take effect once the interim final rule controlling the drug is issued. The date of approval is defined as the later of the approval of the application or the issuance of the interim final rule. Additionally, the effective date of approval for biological products is also addressed in the amendment to Section 351 of the Public Health Service Act. The CSA specifies that approval of a biological product application will not take effect until the interim final rule is issued. The date of approval is defined as the later of the application approval or the rule issuance. The approval date for animal drugs under the Federal Food, Drug, and Cosmetic Act is determined by the issuance of the interim final rule controlling the drug. The approval date for animal drugs is determined by the issuance of the interim final rule controlling the drug, as stated in the Federal Food, Drug, and Cosmetic Act. Conditional approval of a drug will not take effect until the interim final rule controlling the drug is issued under the Controlled Substances Act. The approval date for animal drugs is determined by the issuance of the interim final rule as per the Federal Food, Drug, and Cosmetic Act. Conditional approval of a drug under the Federal Food, Drug, and Cosmetic Act will be delayed until the interim final rule controlling the drug is issued in accordance with the Controlled Substances Act. The approval date for designated new animal drugs is dependent on the issuance of the interim final rule. The approval of new animal drugs will be delayed until the interim final rule controlling the drug is issued under the Controlled Substances Act. Newly approved drugs will be scheduled accordingly. The Controlled Substances Act is amended to require the Attorney General to issue an interim final rule controlling drugs recommended by the Secretary of Health and Human Services within 90 days of receiving the recommendation. The approval of new animal drugs will be delayed until the rule is issued. The Attorney General must issue an interim final rule controlling drugs recommended by the Secretary of Health and Human Services within 90 days. The rule becomes immediately effective without needing to show good cause, allowing for public comment and hearings before a final rule is issued. The interim final rule allows for public comment and hearings before the Attorney General issues a final rule on drug scheduling criteria. Additionally, an extension of the patent term is provided for drug products under specific conditions defined by the Secretary of Health and Human Services. The Secretary of Health and Human Services notifies sponsors of drug applications for potential Controlled Substances Act controls. The drug product is considered approved or indexed under relevant provisions and permitted for commercial marketing or use. The \"covered date\" is determined by the approval or conditional approval date under specific acts. The Controlled Substances Act regulates drug development and manufacturing for clinical trials. The Attorney General must register applicants within 180 days of application acceptance. The Attorney General must register applicants within 180 days of application acceptance for manufacturing controlled substances for clinical trials. Additionally, re-exportation among members of the European Economic Area is addressed. The Controlled Substances Import and Export Act is amended to allow re-exportation among members of the European Economic Area, with specific conditions outlined for exporting controlled substances between countries within the EEA. The Controlled Substances Import and Export Act is amended to allow re-exportation among members of the European Economic Area, with specific conditions outlined for exporting controlled substances between countries within the EEA. Subsequent re-exportations must meet certain conditions for each country involved. The Controlled Substances Import and Export Act is amended to allow re-exportation among members of the European Economic Area. Specific conditions are outlined for exporting controlled substances within the EEA, including documentation and information requirements for each re-exportation. The Attorney General is limited in promulgating regulations for certain controlled substances and narcotic drugs. The Attorney General is restricted from enforcing regulations that hinder re-exportation of controlled substances among European Economic Area countries, including requirements for specific timeframes or information disclosure before exportation. The curr_chunk is about the roles of the Speaker of the House of Representatives and the Vice President of the United States as President of the Senate."
}